Generation of CD34⁺CD43⁺ Hematopoietic Progenitors to Induce Thymocytes from Human Pluripotent Stem Cells.

ABSTRACT: Immunotherapy using primary T cells has revolutionized medical care in some pathologies in recent years, but limitations associated to challenging cell genome edition, insufficient cell number production, the use of only autologous cells, and the lack of product standardization have limited its clinical use. The alternative use of T cells generated in vitro from human pluripotent stem cells (hPSCs) offers great advantages by providing a self-renewing source of T cells that can be readily genetically modified and facilitate the use of standardized universal off-the-shelf allogeneic cell products and rapid clinical access. However, despite their potential, a better understanding of the feasibility and functionality of T cells differentiated from hPSCs is necessary before moving into clinical

SUBMITTER: Flippe L 

PROVIDER: S-EPMC9777438 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature